- Home
- GSIW vs VCNX Comparison
GSIW vs VCNX Comparison
Compare GSIW & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- VCNX
- Stock Information
- Founded
- GSIW 2016
- VCNX 2001
- Country
- GSIW Hong Kong
- VCNX United States
- Employees
- GSIW N/A
- VCNX N/A
- Industry
- GSIW
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- VCNX Health Care
- Exchange
- GSIW Nasdaq
- VCNX Nasdaq
- Market Cap
- GSIW 10.5M
- VCNX 10.5M
- IPO Year
- GSIW 2023
- VCNX N/A
- Fundamental
- Price
- GSIW $0.57
- VCNX $1.41
- Analyst Decision
- GSIW
- VCNX
- Analyst Count
- GSIW 0
- VCNX 0
- Target Price
- GSIW N/A
- VCNX N/A
- AVG Volume (30 Days)
- GSIW 156.5K
- VCNX 96.1K
- Earning Date
- GSIW 12-31-2024
- VCNX 11-14-2024
- Dividend Yield
- GSIW N/A
- VCNX N/A
- EPS Growth
- GSIW N/A
- VCNX N/A
- EPS
- GSIW N/A
- VCNX N/A
- Revenue
- GSIW $1,408,469.00
- VCNX $388,000.00
- Revenue This Year
- GSIW N/A
- VCNX N/A
- Revenue Next Year
- GSIW N/A
- VCNX N/A
- P/E Ratio
- GSIW N/A
- VCNX N/A
- Revenue Growth
- GSIW N/A
- VCNX N/A
- 52 Week Low
- GSIW $0.53
- VCNX $1.25
- 52 Week High
- GSIW $15.99
- VCNX $13.02
- Technical
- Relative Strength Index (RSI)
- GSIW 36.17
- VCNX 27.23
- Support Level
- GSIW $0.55
- VCNX $3.34
- Resistance Level
- GSIW $0.64
- VCNX $4.35
- Average True Range (ATR)
- GSIW 0.06
- VCNX 0.50
- MACD
- GSIW 0.04
- VCNX -0.19
- Stochastic Oscillator
- GSIW 16.67
- VCNX 4.87
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.